| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 25,500 | 25,800 | 09:41 |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.03. | BASTIDE: 2025-2026 half-year results | 893 | Actusnews Wire | Recurring operating margin: 9.0%, in line with the annual target
Operating profit up 12.5%
Operating free cash flow: €24.3 million, a threefold increase in one year
Significant improvement... ► Artikel lesen | |
| 12.02. | BASTIDE: Organic growth of 8.2% in first-half 2025-2026: Confirmed excellent growth momentum in home healthcare services: 9.2% / Accelerated growth in the Homecare business, up 6.5% // 2025-2026 targets confirmed | 413 | Actusnews Wire | Caissargues, February 12, 2026 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-half 2025-2026, ending December 31, 2025.
In... ► Artikel lesen | |
| 13.11.25 | BASTIDE: Organic growth of 8.3% in first-quarter 2025-2026: Sustained growth in home healthcare services, up 10.7% / Homecare business up 4.7%, driven by the healthcare institutions business (up 8.5%) | 488 | Actusnews Wire | Caissargues, November 13, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has published its revenue for first-quarter 2025-2026, ending September 30, 2025.
In... ► Artikel lesen | |
| 28.10.25 | BASTIDE: 2025-2026 financial calendar | 1.021 | Actusnews Wire | Caissargues, October 28, 2025
Events
Dates*
2025-2026 Q1 Revenue
Thursday November 13, 2025
2025-2026 H1 Revenue
Thursday February 12, 2026
2025-2026 H1 Results
Wednesday... ► Artikel lesen | |
| BASTIDE LE CONFORT MEDICAL Aktie jetzt für 0€ handeln | |||||
| 22.10.25 | BASTIDE: 2024-2025 annual results in line with targets // 2025-26 outlook: Revenue of over EUR 510 million and recurring operating margin around 9%, Leverage of less than 3x and decrease in financial expenses | 836 | Actusnews Wire | Caissargues, October 22, 2025 - Groupe Bastide, a leading European provider of home healthcare services, has announced its 2024-2025 annual results at June 30, 2025. The 2024-2025 annual consolidated... ► Artikel lesen | |
| 24.09.25 | BASTIDE: Groupe Bastide completes the sale of Baywater Healthcare to Sapio Group | 779 | Actusnews Wire | Caissargues, September 24, 2025
In line with the timetable set out in its 30 June 2025 communication announcing the agreement to sell Baywater Healthcare, a leading player in the UK respiratory... ► Artikel lesen | |
| 04.09.25 | BASTIDE: 2024-2025 revenue target met // 2024-2025 revenue from continuing operations: EUR 491 million, up 8% ( EUR 561 million, excluding impact of disposals) | 568 | Actusnews Wire | Caissargues, September 4, 2025
Groupe Bastide has published its annual revenue for 2024-2025. In accordance with IFRS 5, reported revenue relates exclusively to continuing operations, and no... ► Artikel lesen | |
| 30.06.25 | BASTIDE: Bastide Groupe Sells Baywater Healthcare To Sapio Group | 730 | Actusnews Wire | Crewe, United Kingdom & Monza, Italy - 30th June 2025
Bastide le Confort Medical SA (hereinafter "Groupe Bastide") today announced that it has agreed to the sale of its subsidiary Baywater Healthcare... ► Artikel lesen | |
| 09.06.25 | BASTIDE: Disposal of CICADUM and MEDSOFT | 610 | Actusnews Wire | Caissargues, June 9, 2025
Bastide Groupe announced today the disposal of its French subsidiaries, Cicadum, 51%-owned, (signing subject to financing condition precedent) and Medsoft, 100%-owned... ► Artikel lesen | |
| 05.06.25 | BASTIDE: Disposal of DORGE and DYNA MEDICAL in Belgium | 587 | Actusnews Wire | Caissargues, June 5, 2025
Bastide Groupe announced today the disposal of its Belgian subsidiaries, Dorge Medic, which specializes in the sale and rental of medical equipment and products for... ► Artikel lesen | |
| 04.06.25 | BASTIDE: Respiratory care therapy: Baywater wins London region tender and consolidates its leading position in the UK | 537 | Actusnews Wire | Caissargues, June 4, 2025
After being chosen one year ago by the National Health Service (NHS) to be the exclusive operator for respiratory care (oxygen therapy) in the East of England region... ► Artikel lesen | |
| 15.05.25 | BASTIDE: Continued strong organic growth in Q3 2024-2025 at +7.7%: Home healthcare services up 10.4% and recovery of Homecare activities confirmed / 2024-2025 targets confirmed | 528 | Actusnews Wire | Caissargues, May 15, 2025
In € millions
2023-2024
published
2023-2024*
Adjusted
2024-2025
published
Change
First-quarter revenue
127.9
122.7
133.8
+9.1%
Second-quarter... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ANSELL | 16,800 | -2,89 % | ANSELL LIMITED: Chief Financial Officer Resignation | ||
| AMBEA | 12,450 | +0,97 % | Ambea AB: Ambea increases growth pace to meet care needs in the Nordics - new care home in Denmark | Ambea is expanding its operations in the Nordic region. Within the Danish business area Altiden, an agreement has been signed to operate a new care home in Munkebo, Kerteminde Municipality.
The new... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 46,010 | -0,07 % | BrightSpring Health Services, Inc.: BrightSpring Health Services Completes Sale of ResCare Community Living to Sevita | LOUISVILLE, Ky., March 31, 2026 (GLOBE NEWSWIRE) -- BrightSpring Health Services, Inc. ("BrightSpring" or the "Company") (NASDAQ: BTSG), a leading provider of home and community-based pharmacy and... ► Artikel lesen | |
| BILLIONTOONE | 80,61 | -2,37 % | BillionToOne, Inc.: BillionToOne to Report First Quarter 2026 Financial Results on May 6, 2026 | ||
| GERRESHEIMER | 20,800 | +17,51 % | Gerresheimer muss SDAX verlassen - exotischer Nachrücker | Es hat sich bereits abgezeichnet: Der angeschlagene Spezialverpackungshersteller Gerresheimer muss den SDAX bereits zum morgigen 10. April verlassen. Die Düsseldorfer haben es versäumt, den testierten... ► Artikel lesen | |
| BETA BIONICS | 13,020 | +10,20 % | Beta Bionics, Inc.: Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026 | IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial... ► Artikel lesen | |
| FRESENIUS | 44,310 | +0,64 % | FRESENIUS SE & CO KGAA: Struktur in der Ruhe | ||
| FRESENIUS MEDICAL CARE | 38,450 | -0,62 % | Shortseller-Positionen aktuell: u.a. Carl Zeiss Meditec, Evonik, FMC, Gerresheimer, GFT, MTU, Nordex, Ströer | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
| HEARTFLOW | 29,190 | +0,59 % | Heartflow, Inc.: Heartflow Files Patent Infringement Lawsuit Against Cleerly | MOUNTAIN VIEW, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that it has filed... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 25,700 | +4,51 % | PROCEPT BioRobotics to Report First Quarter 2026 Financial Results on April 29, 2026 | ||
| GENEDX | 67,32 | +0,69 % | Jefferies bestätigt Kaufempfehlung für GeneDx und verweist auf geringe Marktdurchdringung | ||
| PROGYNY | 17,400 | +1,34 % | Progyny, Inc. Announces Third Quarter 2025 Results | Reports Revenue of $313.3 Million, Reflecting 9.3% GrowthRaises Full Year Guidance to Reflect Continued Strength in Member EngagementSelling Season Yields Over 80 New Clients, 900,000 New Lives, and... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,920 | -1,69 % | Alignment Healthcare Reports Fourth Quarter and Full-Year 2025 Results; Beats High-End of Guidance Across All Key Metrics | Delivers full-year revenue of $3.95 billion, representing 46.1% growth year-over-year Exceeds high-end of fourth quarter and full-year guidance across all key metrics: membership, revenue, adjusted... ► Artikel lesen | |
| HIMS & HERS HEALTH | 22,680 | +10,10 % | Hims & Hers-Aktie: Neue Chancen nach dem Hype? | Die Aktie von Hims & Hers Health hat nach einer Zeit voller Hype und überschwänglichen Erwartungen in den vergangenen Monaten massiv gelitten. Nach einem deutlichen Kursrückgang rückt nun die Frage... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL | 6,290 | 0,00 % | ANTERIS TECHNOLOGIES GLOBAL CORP.: Notification regarding unquoted securities - AVR |